Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)

NCT02959437 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02959437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
February 27, 2017
Completion date
March 2, 2020
Enrollment
70 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, metastatic cancer, solid tumors